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Abstract
Background: There is a strong rationale for the use of agents with film-forming protective properties, like xyloglucan,
for the treatment of acute diarrhea. However, few data from clinical trials are available.
Methods: A randomized, controlled, open-label, parallel group, multicentre, clinical trial was performed to evaluate the
efficacy and safety of xyloglucan, in comparison with diosmectite and Saccharomyces in adult patients with acute
diarrhea due to different causes.
Patients were randomized to receive a 3-day treatment. Symptoms (stools type, nausea, vomiting, abdominal pain and
flatulence) were assessed by a self-administered ad-hoc questionnaire 1, 3, 6, 12, 24, 48 and 72 h following the first
dose administration. Adverse events were also recorded.
Results: A total of 150 patients (69.3 % women and 30.7 % men, mean age 47.3 ± 14.7 years) were included (n = 50 in
each group). A faster onset of action was observed in the xyloglucan group compared with the diosmectite and S.
bouliardii groups. At 6 h xyloglucan produced a statistically significant higher decrease in the mean number of type 6
and 7 stools compared with diosmectite (p = 0.031). Xyloglucan was the most efficient treatment in reducing the
percentage of patients with nausea throughout the study period, particularly during the first hours (from 26 % at
baseline to 4 % after 6 and 12 h). An important improvement of vomiting was observed in all three treatment groups.
Xyloglucan was more effective than diosmectite and S. bouliardii in reducing abdominal pain, with a constant
improvement observed throughout the study. The clinical evolution of flatulence followed similar patterns in
the three groups, with continuous improvement of the symptom. All treatments were well tolerated, without
reported adverse events.
Conclusions: Xyloglucan is a fast, efficacious and safe option for the treatment of acute diarrhea.
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Background
According to the World Health Organization (WHO),
acute diarrhea is defined as the production of three or
more passages of loose or watery stools a day in a 24-h
period, for less than 14 days [1, 2]. In non severe acute
diarrhea of gastroenteritic origin, the stools do not con-
tain visible amounts of blood or mucus [1].
Diarrhea is the expression of an altered homeostasis of
the bowel [3], being intestinal infections (viral, bacterial
and parasitic) the most common cause. Other causes in-
clude side effects of drugs (especially antibiotics), infec-
tions not associated with the gastrointestinal tract, food
poisoning, and allergy [2, 4, 5].
Despite the introduction of oral rehydration therapies,
annual global mortality rate is still high, with an estimate
of 2.5 million people (with higher rates in children [5–7].
After perinatal death (23 %) and acute respiratory infec-
tion (18 %), acute diarrhea represents the third cause of
death (15 %) in children under the age of 5 living in devel-
oping countries [5–7].
The recommended treatment for acute diarrhea con-
sists of oral rehydration. Antibiotics, motility inhibitors
such as loperamide, or substances that decrease water
and electrolyte secretion such as racecadotril can be use-
ful, although with some adverse events (such as the bac-
terial overgrowth induced by motility-reducing drugs),
only in very specific situations [5].
Currently, there is a strong rationale for a new class of
drugs, which may be defined as “mucosal protectors” al-
though further studies are needed to completely assess
the efficacy of these products [3, 8]. Xyloglucan, which
form a bio-protective film is a good candidate in the
treatment of acute diarrhea.
Xyloglucan, extracted from the seeds of the tamarind
tree (Tamarindus indica), has recently received European
approval for restoring the physiological functions of the in-
testinal walls. In the form of capsule form for adults and
powder for paediatric use, xyloglucan has been specifically
formulated for the control and reduction of symptoms re-
lated to diarrheal events of different aetiologies, such as ab-
dominal tension and frequent emissions of faeces [9, 10].
Xyloglucan, if ingested in due amounts, stratify on the in-
testinal mucosa to form a bio-protective film that improves
the resistance of the mucosa to pathologic aggressions and
helps to restore its normal function. Xyloglucan has been
shown to increase the Trans Epithelial Electrical Resistance
(TEER), an index of good function of the mucosal tight
junctions in cell cultures in vitro, confirming its ability to
counteract mucosal permeability after leakage induced with
E. coli exposure. This leakage of mucosal permeability is
typical of diarrhea (Bueno et al., 2015; manuscripts in prep-
aration). The same properties of xyloglucan have also been
demonstrated in vivo by improving the mucosal leak-
age caused by intra-peritoneal injection of E. coli
lipopolysaccharide (LPS - 1 mg/kg) or by intestinal
exposure to cholera toxin (10 g/ml) in adult rats
(Bueno et al., 2015; manuscripts in preparation). Gel-
atin, given with xyloglucan, like other proteins (i.e.
vegetal proteins from pea), acts as a factor favouring
a longer intestinal xyloglucan intestinal bioavailability
prolonging the protective activity of xyloglucan.
Here we describe a randomized, multicenter, open-label
study to assess efficacy, safety and time of onset of the
antidiarrheal effect of xyloglucan, in comparison with two
widely used anti-diarrheal products, S. bouliardii, contain-
ing the yeast probiotic Saccharomyces boulardii, and dios-
mectite, an absorbent activated natural aluminosilicate
clay [1].
Methods
The study protocol was approved by the Decision of the
Ethical Commission for Scientific Research of the “Targu
Mures” University of Medicine and Pharmacy with the no.
60 dated 8 July 2014 and procedures were in accordance
with the ethical standards laid down in the Declaration of
Helsinki, as revised in the year 2000. Written informed con-
sent was obtained from all subjects. Patients were recruited
in different Romanian private offices of general practi-
tioners in the context of their routine clinical practice.
Inclusion criteria were a minimum age of 18 years and
presence of acute diarrhea defined as the occurrence of >3
stools per day graded as 6 or 7 on the Bristol scale [11, 12].
Potential participants were excluded in case of allergy to
one of the products´ ingredients, pregnancy or breastfeed-
ing, recent surgery or serious and/or systemic diseases
(such as inflammatory bowel disease). The use of oral rehy-
dration solutions were not allowed during the study period.
The diagnosis was made according to the investigators’
judgment based on the clinical picture including object-
ive (stools, vomiting and fever) and subjective symptoms
(nausea, abdominal pain and bloating). Consistency of
each stool was classified using the 7-point Bristol Stool
Scale [11, 12].
The patients were randomly assigned to receive xyloglu-
can with gelatin, diosmectite and S. bouliardii at a ratio of
1:1:1. Xyloglucan-gelatin (Tasectan Plus® Novintethical
Pharma, SA) was administered in the form of oral capsules
(containing xyloglucan, gelatin of porcine origin, corn
starch and magnesium stearate). Diosmectite (Smecta®,
Pharmaplan, SA) was administered as powder for oral so-
lution (excipients: glucose monohydrate, saccharin sodium
an orange-vanilla flavor). S. bouliardii was administered as
oral capsules (Ultra-Levura®, Zambon, SA; excipients: lac-
tose monohydrate and magnesium stearate).
During the first enrolment visit, patients from the 3
groups were given a 3-day treatment (two capsules every
6 h in the case of xyloglucan, three sachets/day in the
case of diosmectite and 2 capsules/day in the case of S.
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bouliardii), with the first dose being administered at the
time of recruitment (visit 1). Patients were instructed to
return all packages of the used and unused product at
the post-treatment visit (visit 2, 72 h after visit 1).
During visit 1, patients also received the patient’s daily
diary, to assess the consistency of stools and the presence
of diarrheal symptoms (both objective and subjective) at 1,
3, 6, 12, 24 and 48 h following the first dose administration.
Stools emissions (including number of emissions/day), with
mucus and/or blood, were recorded and consistency of
each stool was assessed using the 7-point Bristol Stool
Scale (type 1 corresponds to separate hard lumps, like nuts
while type 7 corresponds to watery, no solid pieces, entirely
liquid) [11, 12]. The presence of subjective symptoms such
as nausea, vomiting (including number of vomits/day), ab-
dominal pain and flatulence was also assessed.
At visit 2, which took place 72 h after visit 1, the investi-
gators reviewed the patient’s daily diary. During this visit,
a symptoms assessment was also performed by patient’s
interview and exploration, to assess whether healing was
achieved or treatment should be continued. All these data
were transferred into the patient’s case report form (CRF).
The primary efficacy variable was the variation of the
prevalence of diarrheal symptoms during the 3-day treat-
ment and the rapidity of action of the studied products in
the intention-to-treat (ITT) population, defined as all ran-
domized patients who had at least one post-treatment
measurement.
The primary safety variable was the prevalence of ad-
verse events in the three groups of patients in the safety
population, defined as all patients who received at least
one dose of the studied product.
Sample size (n = 150, n = 50 in each group) was calcu-
lated to have a 80 % power to show, with 95 % probabil-
ity, differences in the prevalence of diarrheal symptoms.
Descriptive analyses (within-patient n, mean, median,
standard deviation, minimum and maximum) were per-
formed for quantitative variables and frequency counts by
category were calculated for qualitative variables. Following
the results of normality tests (Kolmogorov-Smirnow test),
data obtained at the two visits (baseline and at day 3) were
compared by means of Friedman’s Anova and Kendall’s co-
efficient of concordance for non-parametric dependent
data. Comparisons of data obtained at a certain visit among
the three treatments were performed by means of Mann–
Whitney U test for non-parametric and independent data.
Two-sided p-values were obtained and statistically signifi-
cant results were declared if p < 0.05.
Results
A total of 150 patients were included in the study (50 in
each group). All randomized patients had at least one
post-treatment measurement and received all doses of
the product, thus the ITT, PP and safety populations co-
incided (see flow chart in Fig. 1).
Table 1 shows the demographic characteristics of the
patients. The groups were homogeneous, with a preva-
lence of women in the whole sample (69.3 % women vs
30.7 % men) and in all three groups and with a mean
age of 47.3 years (Table 1).
Fig. 1 Study flow chart. *No subjects were Lost to Follow-up or Discontinued due to the short period of the study (72 hours)
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During the first 24 h of treatment, the xyloglucan group
showed a faster onset of action and improvement of diar-
rheal symptoms, measured as mean number of type 6 and
7 stools, compared with the diosmectite and S. bouliardii
groups. Accordingly, in the xyloglucan group the highest
reduction of the number of type 6 and 7 stools was ob-
served at 6 h with an effect that was statistically significant
compared with diosmectite group (p = 0.031) (Table 2). The
highest effect of diosmectite was observed at 12 and 24 h,
although no statistically significant differences with xyloglu-
can group were found (Fig. 2). On the contrary, a higher ef-
ficacy was observed in xyloglucan group in comparison
with S. bouliardii group at 12 and 24 h. At 48 and 72 h
there were no statistically significant differences among the
three groups in terms of efficacy (Fig. 2). As a general rule,
both xyloglucan and diosmectite groups showed greater ef-
ficacy during the entire treatment period, compared with S.
bouliardii (Table 2) (Fig. 2)
A higher efficacy of xyloglucan in reducing the per-
centage of patients with nausea was observed through-
out the study period, particularly during the first hours.
The percentage of patients with nausea progressively de-
creased starting from the beginning of xyloglucan treat-
ment. 72 h after visit 1 only 2 % of patients treated with
xyloglucan had nausea (Fig. 3). In the diosmectite group,
the percentage of patients with nausea increased during
the first hour post-administration, from 20 % at visit 1
to 30 %, and then decreased to 14 % at 3 h, 8 % after 6 h
and 4 % after 12 and 24 h. At 48 h after visit 1, no pa-
tients had nausea, while at visit 2, a 4 % of patient had it
(Fig. 3). Finally, in the group treated with S. bouliardii,
the prevalence of nausea progressively decreased from
28 % at visit 1 to 2 % at visit 2 (Fig. 3).
An important improvement of vomiting was observed
in all three treatment groups, with null percentages at 6
and 12 h after visit 1. At 24 h, 2 % of the patients in
xyloglucan group and diosmectite group had vomiting
Table 1 Demographic characteristics among groups
Statistic variable Xyloglucan Diosmectite S. bouliardii Total p-value
Gender (F/M) n (%) 38 (76.0)/12 (24.0) 33 (66.0)/17 (34.0) 33 (66.0)/17 (34.0) 104 (69.3)/46 (30.7) 0.223
Age (years) Mean (SD) 48.4 (14.5) 46.3 (16.9) 47.1 (12.5) 47.3 (14.7) 0.199
F female, M male, SD standard deviation
No statistically significant differences between treatment groups were noted regarding the demographic characteristics
Table 2 Evolution of the mean number of dehydrating stools
(type 6 and 7) during the study period
Time points Xyloglucan Diosmectite S. bouliardii p
1 h 0.50 0.64 0.78 X v D: 1.00
X v S: 1.00
D v S: 0.80
3 h 0.54 0.54 1.03 X v D: 1.00
X v S: 0.99
D v S: 1.00
6 h 0.20 0.56 0.53 X v D: 0.03
X v S: 1.00
D v S: 1.00
12 h 0.20 0.34 0.52 X v D: 0.70
X v S: 1.00
D v S: 0.52
24 h 0.08 0.20 0.42 X v D: 0.72
X v S: 1.00
D v S: 1.00
48 h 0.02 0.14 0.36 X v D: 1.00
X v S: 1.00
D v S: 1.00
72 h 0.07 0.20 0.41 X v D: 1.00
X v S: 1.00
D v S: 1.00
0.50
0.54
0.20 0.20
0.08
0.02
0.07
0.64
0.56
0.34
0.20
0.14
0.20
0.78
1.03
0.53 0.52
0.42
0.36
0.41
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1 3 6 12 24 48 72
Xyloglucan
Diosmectite
Sbouliardii
0.50 0.54
0.20 0.20
0.08
0.64 0.56
0.34
0.20
0.78
1.03
0.53 0.52
0.42
0.00
0.20
0.40
0.60
0.80
1.00
1.20
b
1 3 6 12 24
Xyloglucan
Diosmectite
Sbouliardii
Fig. 2 Clinical evolution of diarrheal symptoms (mean number of type
6 and 7 stools) among groups. a Mean number of type 6 and 7 stools
during the first 24 h. b Mean number of type 6 and 7 stools during the
study period
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and no patients had vomiting at this time point in the S.
bouliardii group (Fig. 4).
Xyloglucan was more effective than diosmectite and S.
bouliardii in reducing abdominal pain, with a constant
improvement observed throughout the study period. In
the groups treated with diosmectite and S. bouliardii, an
increase in the percentage of patients with abdominal pain
was observed within the first hour post-visit 1. At visit 2,
the lowest percentage of patients with abdominal pain was
recorded in xyloglucan group (10 %), in comparison with
diosmectite (22 %) and S. bouliardii (12 %) groups (Fig. 5).
The evolution of flatulence followed similar patterns
in the three groups, with a slight worsening during the
first hour after visit 1 and continuous improvement until
visit 2. The greatest improvement was reported in pa-
tients of xyloglucan group, with 10 % of patients with
flatulence at visit 2, compared with diosmectite (30 %)
and S. bouliardii (18 %) groups (Fig. 6).
Adherence was 100 % in the 3 groups.
All treatments were safe and well tolerated, with no
adverse reaction being reported during the study.
Discussion
The emergence of new protective agents of the intestinal
mucosa with improved film forming efficacy, such as
xyloglucan, offers new alternatives for a more efficient
control of diarrheal diseases [3, 13].
In the present study, we assessed the efficacy and
safety of xyloglucan, in comparison with diosmectite and
S. bouliardii, widely used products for the treatment of
acute diarrhea. These results are also in line with other
studies with xyloglucan, in comparison with oral rehy-
dration solution [9].
We found that xyloglucan is efficacious to rapidly im-
prove the main symptoms of acute diarrhea, equal or
better than diosmectite and S. bouliardii [14–16].
Fig. 3 Percentage of patients with nausea during the study period
Fig. 4 Percentage of patients with vomiting during the study period
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One of the main findings of this study is the faster on-
set of action observed in the xyloglucan group compared
with diosmectite and S. bouliardii.
Such a rapid onset of action is particularly desirable in
the treatment of acute nonspecific diarrhea [17], to de-
crease severity of symptoms, dehydration and risk of
transmission in case of diarrhea of infectious origin [18].
We also observed a rapid effect of xyloglucan in redu-
cing vomiting, another important symptom causing de-
hydration [19]. It should be noted that prevalence of
vomiting at visit 1 was higher in the xyloglucan group
than in the rest of groups. However, during the first 3 h,
we observed in the xyloglucan group, a marked sustained
decreased in the percentage of patients with this symp-
toms. In the other groups, although initial prevalence was
lower, this sustained decreased during the first 3 h was
not observed as clear as in the xyloglucan group.
Also of relevance is the reduction of abdominal pain ob-
served in patients treated with xyloglucan, in comparison
with diosmectite and S. bouliardii, probably due to the dir-
ect protective effect xyloglucan on the intestinal wall, which
reduces the exposure of intestinal cells to inflammatory
agents that trigger abdominal pain. This mechanism of ac-
tion can explain the differences observed with the probiotic
S. bouliardii, whose effect on diarrhea is thought to be re-
lated to competition with pathogenic microorganisms for
nutrients on adhesion sites, and possibly by secretion of
probiotic compoundsthat inhibit the growth of pathogenic
microorganisms [1]. As already reported [1], the efficacy of
this probiotic in acute diarrhea has been related to stools
consistency. Rapid reduction of abdominal pain is relevant
in the control of diarrhea, increasing patient’s quality of life
and assuring a rapid recovery [20]. It is also of rele-
vance the better effect of xyloglucan, in comparison
Fig. 5 Percentage of patients with abdominal pain during the study period
Fig. 6 Percentage of patients with flatulence during the study period
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with diosmectite, an adsorbent clay mineral with coating
protective properties [1].
Reduction of abdominal pain is also important for the
whole management of diarrhea, in which, the adminis-
tration of anti-inflammatory drugs as NSAIDs can alter
the integrity of mucus layer [1, 2, 4, 5].
Finally, as expected, all three treatments reduced flatu-
lence, a symptom that importantly decreases the patient’s
quality of life. In the case of gelatin and xyloglucan, the
formation of the biofilm could reduce bacterial prolifera-
tion and the formation of gas, although further preclinical
studies should be performed to demonstrate it. In the case
of diosmectite, it has been found that diosmectite can re-
duce the production of hydrogen in the colon during mi-
crobial fermentation [1, 21].
The present study is part of the development of new food
supplements that contain mucosal protectors, with film-
forming properties. In the case of xyloglucan, we have dem-
onstrated its properties in preclinical in vitro and in vivo
models. This study is part of the clinical development of
xyloglucan, and the results obtained are also in line with
those obtained in another study in children with acute
gastroenteritis [22]. As future research, other studies could
be done to assess the effect of xyloglucan in other gastro-
intestinal diseases associated with diarrheal symptoms.
Conclusions
In conclusion the administration of xyloglucan is an effi-
cacious and safe option in the clinical practice for the
treatment of acute diarrhea, with a rapid onset of action
in reducing diarrheal symptoms.
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